par Marray, Tristan
;Hernalsteens, Olivier
;Verdikt, Roxane
;Dutilleul, Antoine
;Vanhulle, Caroline
;Bendoumou, Maryam
;Oumata, Nassima;Monceaux, Valerie;Verhasselt, Bruno;Galons, Hervé;Ciuffi, Angela;Sáez-Cirión, Asier;Rohr, Olivier;Van Lint, Carine 
Référence Conference on HIV Persistence & Eradication 2026(12th Edition: 6-9 Décembre, 2026: Cabo San Lucas, Mexico)
Publication Non publié, s.d.
;Hernalsteens, Olivier
;Verdikt, Roxane
;Dutilleul, Antoine
;Vanhulle, Caroline
;Bendoumou, Maryam
;Oumata, Nassima;Monceaux, Valerie;Verhasselt, Bruno;Galons, Hervé;Ciuffi, Angela;Sáez-Cirión, Asier;Rohr, Olivier;Van Lint, Carine 
Référence Conference on HIV Persistence & Eradication 2026(12th Edition: 6-9 Décembre, 2026: Cabo San Lucas, Mexico)
Publication Non publié, s.d.
Abstract de conférence
| Résumé : | BackgroundThere is increasing evidence for the physiological relevance of myeloid HIV-1 reservoirs such as brain microglia and urethral macrophages. However, the molecular mechanisms of HIV-1 gene expression in myeloid infected cells are still poorly understood. The HIV-1 intragenic cis-regulatory region (IRR) located in the pol gene exhibits an enhancer activity on the 5’LTR promoter. The IRR possesses multiple binding sites for various cellular transcription factors. Here, we characterized the functional involvement of several binding sites for the myeloid-specific transcription factor PU.1, known to be a pioneer transcription factor inducing the opening of heterochromatin in enhancers, in the IRR-mediated control of HIV-1 gene expression in monocytes/macrophages.MethodsChromatin immunoprecipitation (ChIP-qPCR), formaldehyde-assisted isolation of regulatory elements (FAIRE-qPCR), assay for transposase-accessible chromatin with high-throughput sequencing (ATAC-Seq), electrophoretic mobility shift assays (EMSAs), p24 ELISA, purification of primary cells from blood samples, infection assays, knockdown by RNA interference. Results We demonstrated the in vivo recruitment of PU.1 to the HIV-1 intragenic enhancer in infected cell lines from myeloid origin. We physically characterized in vitro PU.1 binding to the different intragenic PU-boxes and identified mutations abolishing PU.1 binding without altering the underlying amino acid sequence of the pol gene. We demonstrated the role of the PU-boxes in the enhancer activity of the IRR, in its epigenetic profile, in its enhancer-related cofactors recruitment and finally its chromatin accessibility using mutated viral particles in single-round infection experiments in myeloid cell lines. Next, we showed the importance of the intragenic PU.1 binding sites in HIV-1 replication using primary monocytes-derived macrophages isolated from uninfected individuals and demonstrated the functional role of the PU.1 factor by RNA interference. To overcome HIV-1 persistence, targeted approaches for each specific reservoir are needed. As a proof-of-concept, we revealed the potential therapeutic application of a specific inhibitor interfering with PU.1 binding as a new anti-HIV-1 approach.ConclusionsThe HIV-1 intragenic enhancer brings an additional factor in an already complex network of regulators affecting the level of HIV-1 transcription. Such complexity could allow a finer-tuned regulation that might find its purpose when HIV-1 transcription needs to be moderately or transiently modified within different cellular and chromatin environments. The role of the IRR in HIV-1 gene expression regulation opens new avenues for HIV cure approaches targeting the heterogeneous cellular and tissue latent reservoirs of virus. |



